FK506-binding protein (FKBP) is a monomer that binds to FK506, rapamycin, and related ligands. The F36M substitution, in which Phe36 in the ligand-binding pocket is changed to Met, leads to formation of antiparallel FKBP dimers, which can be dissociated into monomers by ligand binding. This FKBP(M) mutant has been employed in the mammalian secretory pathway to generate aggregates that can be dissolved by ligand addition to create cargo waves. However, when testing this approach in yeast, we found that dissolution of FKBP(M) aggregates was inefficient. An improved reversibly dimerizing FKBP formed aggregates that dissolved more readily. This FKBP(L,V) mutant carries the F36L mutation, which increases the affinity of ligand binding, and the I90V mutation, which accelerates ligand-induced dissociation of the dimers. The FKBP(L,V) mutant expands the utility of reversibly dimerizing FKBP.
Introduction
Human FKBP, also known as FKBP12, is a monomeric 12-kDa cis/trans peptidyL-prolyl isomerase and a member of a family of proteins that bind the immunosuppressive drugs FK506 and rapamycin. 12 The FKBP-FK506 complex associates with the phosphatase calcineurin, whereas the FKBP-rapamycin complex associates with the FKBP-rapamycin binding (FRB) domain of the kinase mTOR. As a research tool, the FKBP-rapamycin-FRB interaction has been widely used for ligand-inducible heterodimerization of fusion proteins. 9 The cytotoxicity of rapamycin can be avoided by using synthetic ligands that bind to wild-type or mutant forms of FKBP.
When Phe36 in the ligand-binding pocket of FKBP was changed to Met to create the FKBP(M) mutant, a novel property emerged. 33 The altered ligand-binding interface selfassociated so that FKBP(M) formed an antiparallel homodimer, and in the presence of ligand, dimerization was blocked. Expression in mammalian cells of enhanced GFP (EGFP) fused to 4 tandem copies of FKBP(M) resulted in formation of fluorescent aggregates, presumably due to a heterogeneous set of cross-associations between the EGFP-FKBP (M)x4 molecules. Those aggregates could be dissolved by adding ligand.
Reversible aggregation of FKBP(M) has been exploited to create cargo waves in the mammalian secretory pathway. 30 When EGFP-FKBP(M)x4 was targeted to the lumen of the endoplasmic reticulum (ER), it formed aggregates that were too large to exit the ER. Addition of ligand dissolved the aggregates to yield a soluble fluorescent secretory cargo that was incorporated into ER-derived vesicles and transported to the Golgi.
Variations on this method have been used to test models for protein traffic through the Golgi stack. 20, 31, 40 We are interested in using reversible aggregation to create cargo waves in the secretory pathway of the yeast Saccharomyces cerevisiae, which is a popular experimental organism for studying membrane traffic. 18, 28 The specific goal is to test whether secretory cargoes remain in a Golgi cisterna while resident Golgi proteins arrive and depart during cisternal maturation. 24 This prediction about the behavior of secretory cargoes is crucial for validating the cisternal maturation model. 15 However, no good method is yet available for tracking the movement of fluorescent cargoes through the yeast secretory pathway. We observed that when fluorescent proteins were targeted to the yeast ER, GFP variants exited the ER slowly, 10 but the highly soluble tetrameric DsRed variant E2-Crimson 37 exited the ER much faster (E. Papanikou, unpublished observations). E2-Crimson was therefore deemed a good starting point for engineering a fluorescent secretory cargo. Fusion of a single copy of FKBP(M) to tetrameric E2-Crimson was predicted to generate fluorescent aggregates that could be dissolved by adding ligand (Fig. 1) .
For initial characterization, we fused FKBP(M) to E2-Crimson and expressed this construct in the yeast cytosol. Fluorescent aggregates formed and could be dissolved by adding ligand. However, dissolution of the aggregates was relatively slow and required high ligand concentrations. To improve this system, we engineered an alternative dimerizing FKBP mutant that permits faster dissolution of aggregates using lower concentrations of ligand.
Results and discussion
Generation of fluorescent aggregates in the yeast cytosol It was previously shown that expression in mammalian cells of EGFP fused to 4 tandem copies of FKBP(M) resulted in formation of fluorescent aggregates. 33 To replicate this effect in yeast, we expressed EGFP-FKBP(M)x4 from an integrating vector using the strong constitutive TPI1 promoter. Many of the cells showed one or 2 fluorescent aggregates ( Fig. 2A) .
EGFP itself has a weak tendency to dimerize, and this property can dramatically affect the localization of certain fusion proteins. 22, 36, 42 We therefore made an alternative yeast expression construct in which EGFP was replaced with mEGFP, which contains the monomerizing A206K mutation. 42 Yeast cells expressing mEGFP-FKBP(M)x4 showed a diffuse cytosolic fluorescence with few if any aggregates (Fig. 2B) . We infer that aggregate formation with EGFP-FKBP(M)x4 likely involves EGFP dimerization as well as FKBP(M) dimerization.
A conceptually simpler way to generate fluorescent aggregates is to fuse a single copy of FKBP(M) to a tetrameric fluorescent protein (see Fig. 1 ). When FKBP(M) was fused to the C-terminus of E2-Crimson and expressed in yeast, many of the cells showed one or two fluorescent aggregates of varying size (Fig. 3, top panels) . By contrast, when FKBP(M) was replaced with wild-type FKBP, none of the cells had fluorescent aggregates (data not shown). Thus, the E2-Crimson-FKBP(M) construct was deemed promising for the generation of reversible aggregates in yeast cells.
Dissolution of aggregates in a drug-sensitive yeast strain
In an effort to dissolve the E2Crimson-FKBP(M) aggregates, we used a commercially available synthetic ligand of FKBP called SLF. 17 However, when wild-type yeast cells expressing E2-Crimson-FKBP(M) were incubated with 250 mM SLF for up to 2 h, no significant dissolution of the aggregates was seen (Fig. 3, top panels) .
We reasoned that the cells might be removing SLF with the aid of ABC-type pleiotropic drug resistance (PDR) transporter proteins. 32 One of the major drug transporters in S. cerevisiae is Pdr5. In a pdr5D mutant expressing E2-Crimson-FKBP(M), treatment for 15 min with SLF led to substantial dissolution of the aggregates, with many cells showing a uniform weak cytosolic fluorescence and others showing cytosolic fluorescence plus very small aggregates (Fig. 3 , middle panels). But after 1 h the cytosolic fluorescence was no longer visible, and the cells contained multiple small aggregates. Evidently, the cells adapted over time 34, 38 by increasing their capacity to export SLF using transporters other than Pdr5.
Expression of Pdr5 and many other PDR proteins in S. cerevisiae is controlled by the Pdr1 and Pdr3 pair of transcription factors. 32 To achieve a broad and persistent suppression of drug export, we disrupted both the PDR1 and PDR3 genes. In a pdr1D pdr3D double mutant expressing E2-Crimson-FKBP(M), addition of SLF dissolved the aggregates to generate a uniform cytosolic fluorescence that persisted for at least 2 h (Fig. 3 , bottom panels, and data not shown). The pdr1D pdr3D strain was therefore chosen as the starting point for further analysis.
Enhancement of the ligand effect with the F36L mutation
To dissolve E2-Crimson-FKBP(M) aggregates, we used SLF at 250 mM because lower concentrations were less effective. A pdr1D pdr3D strain showed no growth defect in medium containing 250 mM SLF (data not shown), but the use of such high drug concentrations is expensive and raises concerns about nonspecific effects on the cells. These issues could be addressed by identifying a dimerizing FKBP variant with stronger ligand binding. The F36M mutation reduces ligand binding affinities approximately 10-fold, 33 whereas the F36L mutation has only a minimal effect on ligand binding. 8 A possible ability of the F36L mutation to promote dimerization has not been reported. We therefore tested whether dimerization occurred with an F36L mutant of FKBP, here termed FKBP(L). Indeed, E2-Crimson-FKBP(L) formed cytosolic aggregates similar to those seen with E2-Crimson-FKBP(M) (Fig. 4) .
The prediction was that E2-Crimson-FKBP(L) aggregates would dissolve at lower SLF concentrations than E2-Crimson-FKBP(M) aggregates. For this experiment, pdr1D pdr3D cells expressing the aggregating constructs were incubated with varying concentrations of SLF for 30 min. Confocal image stacks were then acquired, and the ratio of punctate to total fluorescence was quantified. Representative images are shown in Figure 4 together with quantitation of the image data. Maximal dissolution of E2-Crimson-FKBP(M) aggregates required 250 mM SLF, whereas maximal dissolution of E2-Crimson-FKBP(L) aggregates required only 25 mM SLF. Thus, the F36L mutation is apparently preferable to F36M for the purpose of ligand-reversible dimerization.
Acceleration of aggregate shrinkage with the I90V mutation
After addition of SLF, aggregates generated with E2-Crimson-FKBP(M) or E2-Crimson-FKBP(L) required up to 5 min or more for complete dissolution. Because a similar time scale is seen for cargo transport through the yeast secretory pathway 24 and our ultimate goal is to produce a nearly synchronous cargo wave, faster dissolution of the aggregates would be useful.
Ligand-induced disruption of the FKBP dimer presumably occurs when the dimer spontaneously dissociates to enable ligand binding. Therefore, a mutation that increases the dissociation rate of the dimer would be expected to accelerate ligand-induced shrinkage of FKBP aggregates. To identify such a mutation, we examined the crystal structure of the FKBP(M) dimer. 33 Residue Ile-90 in the dimerization interface has a hydrophobic interaction with its counterpart in the other subunit. The corresponding residue is Val in many closely related FKBP proteins, 11 suggesting that the less hydrophobic Val should be tolerated at position 90. We introduced the I90V mutation into FKBP(L) to generate FKBP(L,V).
To FKBP(L,V) , we sought to perform live-cell imaging after addition of SLF. Flow chambers have been described for introducing drugs during live-cell imaging of yeast, 4, 21 but those systems were constructed using the polymer polydimethylsiloxane (PDMS), which binds hydrophobic drugs such as SLF. 43 We therefore modified and simplified a commercially available yeast live-cell imaging system 4 to avoid the use of PDMS. As shown in Figure 5A , yeast cells attached to a coverslip with concanavalin A are overlaid with a slab of the hard plastic poly(methyl methacrylate) (PMMA). A channel in the PMMA creates a flow chamber, which is connected to metal tubes that are connected in turn to plastic tubing. Liquid is pulled through the chamber by a nonelectric pressure-driven pump. 25 With this device, we can flow SLF-containing medium over the cells while performing 4D confocal microscopy.
This flow chamber was used to track the shrinkage of cytosolic E2-Crimson-FKBP(L) and E2-Crimson-FKBP(L,V) aggregates after addition of 25 mM SLF. The stacks of confocal images for the individual time points were projected, and the projections were assembled into movies. Figure 5B shows frames from 2 representative movies (Videos 1 and 2). The aggregates varied considerably in size, and accordingly, they took variable amounts of time to dissolve. On average, shrinkage of aggregates was substantially faster with E2-Crimson-FKBP(L,V) than with E2-Crimson-FKBP(L). In Figure 5C , the radii of the aggregates from the 2 representative movies are plotted as a function of time. The inset to Figure 5C shows that with E2-Crimson-FKBP(L,V) the mean time for complete dissolution of an aggregate was only 40 sec, approximately 4 times less than with E2-Crimson-FKBP(L). Thus, the I90V mutation substantially accelerates shrinkage of aggregates.
Conclusions
Reversible aggregates can be generated in the secretory pathway not only with dimerizing FKBP, but also with tools such as the plant photoreceptor protein UVR8, which forms photolabile homodimers. 5 Another way to create a secretory cargo wave is the "retention using selective hooks" (RUSH) system, which employs biotin to release a streptavidin-binding peptide-modified reporter protein from a streptavidin-modified ER-localized hook protein. 3 Each of these methods is likely to have advantages and disadvantages for particular applications. Because dimerizing FKBP has proven to be useful and flexible, we are seeking to adapt it for generating reversible aggregates in the yeast secretory pathway.
As the first step in this project, we used rational mutagenesis to improve the properties of dimerizing FKBP. The widely used FKBP(M) mutant has the F36M mutation, which promotes dimerization but also reduces ligand binding affinities. 33 By contrast, the F36L mutation was reported to have only a minimal effect on ligand binding affinities, 8 and we found that the FKBP(L) mutant dimerizes. Aggregates generated with FKBP(L) dissolve at about 10-fold lower ligand concentrations than aggregates generated with FKBP(M).
Another opportunity for improvement concerned the speed of ligand-induced disruption of the dimer. The dimer dissociates spontaneously at some rate, enabling ligand to bind and to occlude the dimerization interface. Based on this reasoning, we examined the crystal structure of the FKBP(M) dimer, and noted that hydrophobic interactions involving Ile-90 probably contribute to dimerization. 33 We therefore replaced Ile-90 with Val, which is structurally similar but less hydrophobic. The I90V mutation is expected to accelerate spontaneous dissociation of the dimer. Consistent with this prediction, aggregates generated with the FKBP(L,V) mutant, which has both the F36L and I90V mutations, shrink about 4-fold faster after ligand addition than aggregates generated with FKBP(L).
Our characterization of the dimerizing FKBP mutants employed the synthetic FKBP ligand SLF to dissolve fluorescent aggregates in the yeast cytosol, and this approach allowed us to overcome 2 technical hurdles. The first hurdle was that SLF can be exported from yeast cells by drug transporters. Drug resistance is commonly observed in yeast, and is often addressed by deleting genes that encode drug transporters such as Pdr5. 32 However, in a pdr5D strain, SLF has only a transient effect. A likely explanation is that SLF stimulates the synthesis of other drug transporters by means of the transcription factors Pdr1 and Pdr3. 32, 34, 38 Consistent with this interpretation, in a pdr1D pdr3D mutant, SLF persistently dissolves the aggregates. These results emphasize the value of the pdr1D pdr3D combination for obtaining long-lasting sensitivity to a range of drugs. 6 The second hurdle was that SLF is readily absorbed by the plastic PDMS, which is typically used to make flow chambers for live cell imaging. Anecdotally, similar problems are observed with a variety of commonly used hydrophobic drugs, including compounds that disrupt the cytoskeleton (D. Kovar, personal communication). We devised a simple PDMS-free flow chamber that enables SLF to be introduced during live cell imaging. This approach should be useful for diverse experiments in which drugs are applied to yeast or other cell types.
The goal is to apply these advances toward generation of a secretory cargo wave in yeast, but additional technical issues will need to be addressed. For example, translocation of soluble proteins into the yeast ER typically follows a posttranslational pathway, 1, 26 and because E2-Crimson-FKBP(L,V) can fold and oligomerize in the cytosol, this fusion protein is unlikely to cross the ER membrane posttranslationally. A solution is to use the Ost1 signal sequence, which promotes cotranslational translocation 29, 41 and efficiently targets proteins to the ER lumen before they have a chance to fold. 10 Our initial tests indicate that a pre-Ost1-E2-Crimson-FKBP(L,V) construct forms aggregates in the ER lumen, and that the aggregates can be dissolved by SLF (unpublished data). However, export of the solubilized fusion protein from the ER is slow, presumably because export occurs by bulk flow. 39 This limitation can potentially be overcome by appending an ER export signal such as the pro region of prepro-a-factor. 10, 27 Finally, to visualize the fluorescent secretory cargo together with early and late Golgi markers, we will need to extend our protocol for whole-cell 2-color confocal imaging 7,24 to 3 colors. We are working to overcome these challenges in order to visualize secretory cargo traffic in living yeast.
Materials and methods

Strains, plasmids, and reagents
The parental haploid S. cerevisiae strain was JK9-3da (leu2-3,112 ura3-52 rme1 trp1 his4) . 19 Yeast cells were grown in minimal glucose dropout medium (SD) 35 or nonfluorescent minimal medium (NSD) 2 prepared using nutrient mixtures from Sunrise Science Products (San Diego, CA). The PDR5 and PDR1 genes were disrupted by PCR-based gene deletion using a kanamycin resistance cassette, 23 and the PDR3 gene was disrupted in a similar manner using a nourseothricin resistance cassette. 16 DNA constructs were designed with the aid of SnapGene software (GSL Biotech, Chicago, IL), and the Supplemental Materials includes a folder of 5 annotated plasmid map/sequence files that can be opened with SnapGene Viewer (www.snapgene.com/prod ucts/snapgene_viewer). Expression with the integrating vector YIplac204 13 was driven by the strong constitutive TPI1 promoter and the CYC1 terminator. 24 Plasmids were modified by standard methods including primer-directed mutagenesis and Gibson assembly, and critical regions were verified by sequencing. Integrating vectors were linearized and then transformed into yeast cells using lithium acetate 14 for integration at the TRP1 locus. Single-copy integrations were confirmed by PCR using primers 5 0 GTGTACTTTGCAGTTATGACGCCAGATG G3 0 and 5 0 AGTCAACCCCCTGCGATGTATATTTTCCTG3 0 . A 100 mM solution of SLF in ethanol was obtained from Cayman Chemical (Ann Arbor, MI). This drug was diluted in NSD to the desired concentration.
Construction of the flow chamber
A Warner Instruments model YC-1 yeast cell flow chamber, which was based on a published design, 4 was modified as follows. The device was supplied with a PDMS flow chamber containing 1.27-mm outer diameter stainless steel perfusion port tubes that terminated in a 100-mm deep groove in the chamber. Those tubes were removed, and were inserted into a custom fabricated PMMA slab of the same size with a similar groove. The YC-1 chamber immobilizes yeast cells by gently compressing them between a cellulose membrane and a PDMS-coated coverslip. Instead, we omitted the cellulose membrane, and immobilized the cells on a 24£50 mm high precision No. 1.5 coverslip (Marienfeld, Lauda-K€ onigshofen, Germany) that had been coated with concanavalin A as described below under "Fluorescence microscopy." The assembly was sealed with a clear top plate that was screwed into place. With this configuration, the medium flowed directly over the cells and never encountered PDMS.
Medium was flowed into the chamber through 1/32
00
Tygon tubing connected to the stainless steel perfusion port tubes. To minimize leakage, the flow was driven using negative pressure. We employed an inexpensive nonelectric pressure-driven pump, 25 with a tank volume created using 4 140-cc syringes (Healthcare Supply Pros, Austin, TX) that were clamped with the plungers in an extended position using 1.5 £ 4 inch EZ White Snap Clamps (Amazon.com). Pressure was created using a 60-cc syringe that was clamped with the plunger in an extended position using a 0.75 £ 4 inch EZ White Snap Clamp. This setup allowed medium to be flowed over the cells for 10-15 minutes at a rate of approximately 1 mL/min. Presumably, similar results could be obtained using a more conventional electric syringe pump to generate negative pressure.
Fluorescence microscopy
Static images of cells were captured as Z-stacks using a Zeiss LSM 880 confocal microscope equipped with a 1.4-NA 63x oil objective. The Z-stacks were average projected using ImageJ (https://imagej.nih.gov/ij/).
For 4D live-cell imaging, 7 a 5-mL yeast culture was grown overnight in NSD in a baffled flask, and was diluted to an OD 600 of 0.5-0.7 in fresh NSD medium. A 24 £ 50 mm coverslip was coated with freshly dissolved 2 mg/mL concanavalin A (Sigma-Aldrich, St. Louis, MO; product number C2010) for 10 min, then washed with water and allowed to dry. A 250-mL aliquot of the culture was overlaid on the coverslip, and cells were allowed to adhere for 10 min, followed by several rounds of gentle washing with NSD. The coverslip was placed in the flow chamber and sealed while ensuring that the cells remained immersed in NSD the entire time. NSD was pushed through the flow chamber with a syringe to remove any bubbles, and then the Tygon tubing was clamped. The flow chamber was placed on the stage of a Leica SP5 inverted confocal microscope equipped with a 1.4NA 63x oil objective. One end of the Tygon tubing was connected to the negative pressure pump while the other end was placed in a culture tube with SLF-containing medium. To initiate flow of medium, the clamp was removed. Z-stacks were captured at intervals of 5-6 sec.
Individual images were resized, cropped, and processed to adjust brightness and contrast using Adobe Photoshop. To quantify the fraction of a fluorescent construct that was aggregated at a given SLF concentration, a custom ImageJ plugin was used as described in the Supplemental Materials. 4D data sets were converted to videos using ImageJ. 7 To quantify the radius of a fluorescent aggregate at a given time point in a video, a maximum intensity projection of the confocal image stack was processed with ImageJ by calibrating the image in microns, setting a threshold that excluded cytoplasmic signal, and using the Analyze Particles tool to measure the area of the aggregate. The radius was then calculated by dividing the square root of the area by p. To determine the time needed for dissolution of a fluorescent aggregate, the aggregate was tracked using maximum intensity projections until it was no longer visible. 
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